2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
3
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Radiation-induced Injuries in Patients With Rectal Cancer
1
Radiation Injuries
1
Precancerous Conditions
1
Neoplasms, Second Primary
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Head and Neck Fibrosis
1
Fibrosis
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Adenomatous Polyps
1
Interventions
Blood Specimen Collection
8
Magnetic Resonance Spectroscopy
5
Pentoxifylline
4
Liver Transplantation
4
Tenofovir
3
Specimen Handling
3
High-Energy Shock Waves
3
Tocopherols
2
Sorafenib
2
Simvastatin
2
Low-Level Light Therapy
2
Gemcitabine
2
tremelimumab
1
sonidegib
1
sofosbuvir-velpatasvir drug combination
1
ruxolitinib
1
peginterferon alfa-2a
1
navitoclax
1
maltodextrin
1
hepatitis B hyperimmune globulin
1
esmolol
1
epigallocatechin gallate
1
durvalumab
1
contrast agent BR1
1
bavituximab
1
atezolizumab
1
apixaban
1
alpha-Tocopherol
1
adefovir dipivoxil
1
Viusid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fibrosis
×
alpha-Tocopherol
×
Clear all
NCT02898376
2018-08-08
FIBROTHERME
Institut de Cancérologie de Lorraine
Phase 3
Unknown
142 enrolled